On September 09, 2021 Heat Biologics, Inc., a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, reported that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021 (Press release, Heat Biologics, SEP 9, 2021, https://ir.heatbio.com/news/detail/701/heat-biologics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference [SID1234587474]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Heat Biologics’ presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021 at 7:00 AM Eastern Time.

The webcast can be accessed here and on the investor relations section of Heat Biologics’ website at View Source Management will also be participating in one-on-one meetings with qualified members of the investor community throughout the conference.